Dermatology · Woodland Hills, CA
NPI
1568510436
Since 2007
Specialty
Dermatology
Code 207N00000X
Group practices
1
Medicare group memberships
Hospitals
0
Hospital affiliations
5601 de Soto Ave
Woodland Hills, CA, 91367
Phone (818) 719-2000
Groups this clinician bills Medicare through
Medicare paid
-
No Medicare services published
Medicare patients
-
Drug cost, 2024
$762K
2,760 prescriptions
Company payments
-
None reported
Medicare prescription drug claims, 2024
In 2024, the drug Mark Guralnick prescribed most often to Medicare patients was Clobetasol Propionate, with 352 prescriptions and refills. In total Mark Guralnick wrote 2,760 Medicare prescriptions that cost $762K.
| Drug |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2021-11-22.
| Claims |
|---|
| 30-day fills |
|---|
| Patients |
|---|
| Cost |
|---|
| Clobetasol Propionate Generic | 352 | 461 | 186 | $16K |
| Fluorouracil Generic | 332 | 338 | 288 | $13K |
| Minoxidil Generic | 176 | 526 | 68 | $2,712 |
| Triamcinolone Acetonide Generic | 156 | 211 | 98 | $4,921 |
| Retin-A Tretinoin | 150 | 246 | 76 | $6,092 |
| Mometasone Furoate Generic | 147 | 160 | 96 | $5,438 |
| Calcipotriene Generic | 125 | 150 | 95 | $21K |
| Imiquimod Generic | 116 | 125 | 91 | $3,864 |
| Pimecrolimus Generic | 73 | 89 | 46 | $15K |
| Betamethasone Diprop Augmented Betamethasone/Propylene Glyc | 70 | 88 | 32 | $2,786 |
| Ketoconazole Generic | 65 | 170 | 44 | $2,180 |
| Acitretin Generic | 52 | 66 | Under 11 | $8,523 |
| Dupixent Pen Dupilumab | 45 | 45 | Under 11 | $161K |
| Terbinafine Hcl Generic | 44 | 88 | 26 | $547 |
| Metronidazole Generic | 42 | 50 | 20 | $910 |
Brand drugs: 578 claims; generic drugs: 2,182 claims.
Money and other things of value reported by the companies
No payments from drug or medical device companies to Mark Guralnick were reported in the years we have.
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.